title: [CHOP-bleo versus m-BACOD in the treatment of intermediate and high-grade malignant lymphomas].
abstract: Eighty-three patients with malignant lymphoma of intermediate and high histologic subtypes were randomly assigned to receive induction chemotherapy with either of two intensive regimens: CHOP-Bleo (cyclophosphamide, adriamycin, vincristine, prednisone and bleomycin) or m-BACOD (low-dose methotrexate, bleomycin adriamycin, cyclophosphamide, vincristine and dexamethasone). The median follow-up study is 5 years. The two therapies were not significantly different in regard to response rates (52 to 59%), duration of complete remission (27 months vs 24 months) and survival, but m-BACOD was significantly more toxic than CHOP-Bleo. The relative small proportion of long-term disease free-survivors with both regimens underscores the need for other therapeutic approaches.
authors.affiliation: Departamento de Hematología, Hospital de Oncología, Centro Médico Nacional, IMSS, México, D.F.
authors.forename: A
authors.initials: A
authors.lastname: Avilés
authors.forename: J
authors.initials: J
authors.lastname: Huerta
authors.forename: R
authors.initials: R
authors.lastname: Guzmán
authors.forename: G
authors.initials: G
authors.lastname: Zepeda
authors.forename: J C
authors.initials: JC
authors.lastname: Díaz-Maqueo
mesh_terms: D000206:Actuarial Analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008800:Mexico / Q000453:epidemiology; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D012307:Risk Factors; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate
vernacular_title: CHOP-Bleo versus m-BACOD en el tratamiento de linfomas malignos de grados intermedio y alto de malignidad.